Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus nab-paclitaxel and carboplatin as neoadjuvant therapy in early/locally advanced TNBC and HR-low/HER2-negative breast cancer
ChiCTR2500108763Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in triple-negative breast cancer (TNBC) and breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: Breast pathological complete response rate (bpCR) and Total pathological complete response rate (tpCR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR2500108763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108763.